Patents by Inventor Toufike Kanouni

Toufike Kanouni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12172998
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: December 24, 2024
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Patent number: 12122800
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: October 22, 2024
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Robert S. Kania, Jason M. Cox
  • Publication number: 20240293381
    Abstract: The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.
    Type: Application
    Filed: February 2, 2024
    Publication date: September 5, 2024
    Inventors: Lynnie Trzoss, Juan Manuel Betancort, Toufike Kanouni, Michael Brennan Wallace, Amogh Boloor
  • Publication number: 20240279258
    Abstract: Provided herein are inhibitors of TNF-?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-? inhibitory compounds for the treatment of diseases or disorders.
    Type: Application
    Filed: March 4, 2024
    Publication date: August 22, 2024
    Inventor: Toufike KANOUNI
  • Publication number: 20240247014
    Abstract: Provided herein are inhibitors of TNF?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF? inhibitory compounds for the treatment of diseases or disorders.
    Type: Application
    Filed: November 21, 2023
    Publication date: July 25, 2024
    Inventors: Toufike KANOUNI, Chris DE SAVI
  • Publication number: 20240208931
    Abstract: The present disclosure relates to solid state forms of (S)-N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof. Such solid state forms are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of disease.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Andrew PHIMISTER, Jayachandra P. REDDY
  • Patent number: 12018033
    Abstract: Provided herein are inhibitors of protein arginine deiminases (PADs), pharmaceutical compositions comprising the compounds, and methods for using the compounds for the treatment of diseases.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: June 25, 2024
    Assignee: FORWARD THERAPEUTICS, INC.
    Inventor: Toufike Kanouni
  • Publication number: 20240182467
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 29, 2023
    Publication date: June 6, 2024
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • Patent number: 11987560
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: May 21, 2024
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 11987597
    Abstract: Provided herein are inhibitors of TNF-?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-? inhibitory compounds for the treatment of diseases or disorders.
    Type: Grant
    Filed: September 21, 2023
    Date of Patent: May 21, 2024
    Assignee: FORWARD THERAPEUTICS, INC.
    Inventor: Toufike Kanouni
  • Publication number: 20240076306
    Abstract: Provided herein are inhibitors of TNF-?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-? inhibitory compounds for the treatment of diseases or disorders.
    Type: Application
    Filed: September 21, 2023
    Publication date: March 7, 2024
    Inventor: Toufike KANOUNI
  • Publication number: 20240067626
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: June 26, 2023
    Publication date: February 29, 2024
    Inventors: Xiaohu S. OUYANG, Toufike KANOUNI, John S. TYHONAS, Jason M. COX, Robert S. KANIA
  • Patent number: 11890275
    Abstract: The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: February 6, 2024
    Inventors: Lynnie Trzoss, Juan Manuel Betancort, Toufike Kanouni, Michael Brennan Wallace, Amogh Boloor
  • Publication number: 20230416286
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 28, 2023
    Inventors: Toufike KANOUNI, Robert S. KANIA, Jason M. COX
  • Publication number: 20230374015
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 23, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
  • Patent number: 11814384
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: November 14, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Jason M. Cox, John Tyhonas, Robert S. Kania, Subhas J. Chakravorty, Young K. Chen
  • Patent number: 11780862
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: October 10, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Robert S. Kania, Jason M. Cox
  • Publication number: 20230303566
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: February 3, 2023
    Publication date: September 28, 2023
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • Publication number: 20230286917
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Application
    Filed: March 24, 2023
    Publication date: September 14, 2023
    Applicant: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Patent number: 11753395
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: September 12, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania